April 13, 2018 / 11:13 PM / 10 months ago

Patent on Vanda schizophrenia drug upheld by appeals court

A federal appeals court on Friday ended a bid by West-Ward Pharmaceuticals Corp to invalidate a patent on Vanda Pharmaceutical Inc’s schizophrenia drug Fanapt and bring a lower-cost generic version to market.

The U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that a Vanda patent describing a method of using Fanapt to treat schizophrenia was valid and would be infringed by West-Ward’s proposed generic.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2GZ3UDM

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below